Evaluating the Annual Cost of Progression in CD30+ Cutaneous T-cell Lymphomas Following 2L+ Systemic Treatment in Italy
Author(s)
Luca Loreto, MSc1, Beatrice Canali, MSc1, Laura Fioravanti, MSc2, Paolo Morelli, MD PhD2, Silvia Ripoli, MSc2, Chiara Vassallo, MSc1.
1IQVIA SOLUTIONS Italy S.r.l., Milan, Italy, 2Takeda Italia SpA, Rome, Italy.
1IQVIA SOLUTIONS Italy S.r.l., Milan, Italy, 2Takeda Italia SpA, Rome, Italy.
OBJECTIVES: This study estimates the annual cost associated with disease progression of CD30+ cutaneous T-cell lymphomas (CTCL) following second-line and onward (2L+) treatment with either brentuximab vedotin or methotrexate/bexarotene in Italy, including direct healthcare costs and indirect costs.
METHODS: First, a literature review was conducted to identify the patient pathway following CD30+ CTCL progression and the main cost items for each cost category included in the study. Second, resource consumption, annual frequencies of consumption, relative proportion of patients and unit costs for each cost item were assessed based on public reports, literature, national tariffs and Italian gazettes, investigating possible differences between patients progressing after either treatment. Lastly, the annual cost per progressed patient following 2L+ treatment with either brentuximab vedotin or methotrexate/bexarotene was estimated by multiplying the unit cost of each item by its annual frequency and by the relative proportion of patients and deterministic sensitivity analyses (DSAs) were conducted. All retrieved information was integrated and validated with three Italian clinicians, expert in the management of CTCL.
RESULTS: The annual cost per patient of CD30+ CTCL progression was estimated at €164,545 and €75,894 for patients progressing following methotrexate/bexarotene and brentuximab vedotin, respectively. These results were driven by subsequent treatment costs, accounting for 94% (€154,483) and 87% (€65,830) of the two totals. Disease management and indirect costs amounted to €3,236 and €6,826, respectively, for both treatment arms. Hospitalizations accounted for 38% of disease management, while patients’ productivity losses were the main driver (67%) of indirect costs. DSAs results varied between +1% and -36%, obtained when considering a 40% confidential discount on subsequent treatments’ costs.
CONCLUSIONS: This study highlights the high economic burden associated to disease progression of CD30+ CTCL. Furthermore, it shows that the use of brentuximab vedotin as a 2L+ treatment may lead to cost savings in this area.
METHODS: First, a literature review was conducted to identify the patient pathway following CD30+ CTCL progression and the main cost items for each cost category included in the study. Second, resource consumption, annual frequencies of consumption, relative proportion of patients and unit costs for each cost item were assessed based on public reports, literature, national tariffs and Italian gazettes, investigating possible differences between patients progressing after either treatment. Lastly, the annual cost per progressed patient following 2L+ treatment with either brentuximab vedotin or methotrexate/bexarotene was estimated by multiplying the unit cost of each item by its annual frequency and by the relative proportion of patients and deterministic sensitivity analyses (DSAs) were conducted. All retrieved information was integrated and validated with three Italian clinicians, expert in the management of CTCL.
RESULTS: The annual cost per patient of CD30+ CTCL progression was estimated at €164,545 and €75,894 for patients progressing following methotrexate/bexarotene and brentuximab vedotin, respectively. These results were driven by subsequent treatment costs, accounting for 94% (€154,483) and 87% (€65,830) of the two totals. Disease management and indirect costs amounted to €3,236 and €6,826, respectively, for both treatment arms. Hospitalizations accounted for 38% of disease management, while patients’ productivity losses were the main driver (67%) of indirect costs. DSAs results varied between +1% and -36%, obtained when considering a 40% confidential discount on subsequent treatments’ costs.
CONCLUSIONS: This study highlights the high economic burden associated to disease progression of CD30+ CTCL. Furthermore, it shows that the use of brentuximab vedotin as a 2L+ treatment may lead to cost savings in this area.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE433
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Rare & Orphan Diseases